

7-12-2012

# MC3R and MC4R Knockdown via RNA Interference

Danielle N. Mankin  
*Georgia State University*

Follow this and additional works at: [http://scholarworks.gsu.edu/biology\\_theses](http://scholarworks.gsu.edu/biology_theses)

---

## Recommended Citation

Mankin, Danielle N., "MC3R and MC4R Knockdown via RNA Interference." Thesis, Georgia State University, 2012.  
[http://scholarworks.gsu.edu/biology\\_theses/37](http://scholarworks.gsu.edu/biology_theses/37)

This Thesis is brought to you for free and open access by the Department of Biology at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Biology Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [scholarworks@gsu.edu](mailto:scholarworks@gsu.edu).

# MC3R AND MC4R KNOCKDOWN VIA RNA INTERFERENCE

by

DANIELLE MANKIN

Under the Direction of Aaron Roseberry

## ABSTRACT

Melanocortins (MCs) play an important role in feeding, metabolism, and energy expenditure. While melanocortin receptor (MCR) mRNA has been found in the mesolimbic dopamine (DA) pathway, the ability of melanocortins to regulate feeding and other behaviors through actions on the mesolimbic DA system have not been examined. Short-hairpin RNAs (shRNAs) were created targeting MC3R and MC4R and were tested via *in vitro* studies for their ability to knockdown their target receptor. A total of three shRNAs were created targeting each receptor, and each shRNA caused successful knockdown. These shRNAs are tools that can be used for future *in vivo* studies to examine the various behavioral effects of melanocortins on the mesolimbic DA pathway.

INDEX WORDS: Melanocortin, Dopamine, Food intake, RNA interference, Short-hairpin, Mesolimbic dopamine pathway

MC3R AND MC4R KNOCKDOWN VIA RNA INTERFERENCE

by

DANIELLE MANKIN

A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of

Master of Science

in the College of Arts and Sciences

Georgia State University

2012

Copyright by  
Danielle N. Mankin  
2012

MC3R AND MC4R KNOCKDOWN VIA RNA INTERFERENCE

by

DANIELLE MANKIN

Committee Chair: Aaron Roseberry

Committee: Tim Bartness

William Walthall

Electronic Version Approved:

Office of Graduate Studies

College of Arts and Sciences

Georgia State University

August 2012

## ACKNOWLEDGEMENTS

This thesis would not have been possible without the guidance and the help of several individuals. I would like to begin by thanking my peers, especially Lewis Yen and Dereka Moore, for being an unending source of backing and encouragement. I am indebted to Dr. Deborah Baro for allowing me to use her laboratory equipment without which none of my experiments would have been possible. I am also grateful to Dr. Tim Bartness, for not only acting as a part of my thesis committee, but also being a great professor and teaching me much of the groundwork that led to my understanding of neurobiology as a science. I would like to thank Dr. William Walthall for giving me the opportunity to work in his laboratory and always being a source of guidance as an adviser. Lastly, I would like to show my gratitude to my mentor, Dr. Aaron Roseberry, whose encouragement, guidance, and support from the initial to the final steps enabled me to develop a deeper understanding of not only the subject matter and laboratory techniques, but what it means to be a scientist.

## TABLE OF CONTENTS

ACKNOWLEDGEMENTS .....	iv
LIST OF TABLES .....	vii
LIST OF FIGURES .....	viii
1 INTRODUCTION .....	1
1.1 <i>The homeostatic pathway of the hypothalamus</i> .....	1
1.2 <i>Mesolimbic dopamine pathway</i> .....	6
1.3 <i>Mesolimbic Dopamine System and Feeding</i> .....	8
1.4 <i>Reward and the dorsal striatum</i> .....	9
1.5 <i>Mesolimbic and homeostatic feeding pathway interactions</i> .....	10
1.6 <i>Mesolimbic dopamine pathway and melanocortin interactions</i> .....	13
1.7 <i>Research Goals</i> .....	14
2 METHODS/EXPERIMENTAL PROTOCOL .....	15
2.1 <i>Creation of shRNA targeting the MC3R and MC4R</i> .....	15
2.2 <i>ptdTomato-MC3/4R creation</i> .....	17
2.3 <i>shRNA testing in vitro</i> .....	18
2.4 <i>Data Analysis and Statistics</i> .....	19
3 RESULTS .....	19
4 DISCUSSION.....	28

REFERENCES ..... 32



## LIST OF TABLES

<b>Table 1. Targeted mRNA sequences used to create pAAV short-hairpins .....</b>	<b>16</b>
<b>Table 2. Experimental co-transfections into HEK-293 cells.....</b>	<b>18</b>

## LIST OF FIGURES

<b>Figure 1. Breakdown of melanocortin neuropeptides from its original state as a preprohormone .....</b>	<b>2</b>
<b>Figure 2. Projections of POMC and AgRP neurons throughout the rat brain.....</b>	<b>5</b>
<b>Figure 3. Neuropeptides that affect dopamine neurons .....</b>	<b>12</b>
<b>Figure 4. A sample of the known relationships between the homeostatic and reward pathways .....</b>	<b>15</b>
<b>Figure 6. Design of AAV shRNAs.....</b>	<b>17</b>
<b>Figure 5. Schematic of short-hairpin creation used in RNAi.....</b>	<b>17</b>
<b>Figure 7. Sample images showing effectiveness of the MC3R shRNAs on tdTomatoMC3R expression.....</b>	<b>21</b>
<b>Figure 8. MC3R shRNAs decrease expression of tdTomatoMC3R in HEK-293 cells .....</b>	<b>22</b>
<b>Figure 9. Extent of knockdown of the tdTomatoMC3R by the MC3R shRNAs.....</b>	<b>22</b>
<b>Figure 10. Sample images showing effectiveness of the MC4R shRNAs on tdTomatoMC4R expression.....</b>	<b>24</b>
<b>Figure 11. MC4R shRNAs decrease expression of tdTomatoMC4R in HEK-293 cells .....</b>	<b>25</b>
<b>Figure 12. Extent of knockdown of the tdTomatoMC4R by the MC4R shRNAs.....</b>	<b>25</b>
<b>Figure 13. Sample images showing no MC3Rsh2 effect on tdTomatoMC4R .....</b>	<b>26</b>
<b>Figure 14. MC3R shRNAs do not affect expression of tdTomatoMC4R.....</b>	<b>27</b>
<b>Figure 15. Sample images showing no MC4Rsh3 effect on tdTomatoMC3R .....</b>	<b>27</b>
<b>Figure 16. MC4R shRNAs do not affect expression of tdTomatoMC3R.....</b>	<b>28</b>

## 1 INTRODUCTION


Today, it is estimated that 68% of adults and 32% of children in the United States are considered overweight or obese (Ogden et al 2012a; 2012b; Flegal et al 2010). Obesity is shown to have correlations with heart disease, hypertension, stroke, type II diabetes, sleep apnea, various cancers, infertility, and overall decreased life expectancy (Haslam & James 2005). Obesity and food intake are influenced by a variety of psychological factors such as food choice, social interactions, and aesthetics as well as physiological factors such as energy stores, endocrine signals, paracrine signals, and neuropeptides. It is debated how each of these factors works to cause or cease feeding via peripheral and central control. Peripheral cues are an important aspect of food intake control; however, the main focus of this paper will be within the central nervous system.

### *1.1 The homeostatic pathway of the hypothalamus*

Prior to the 1950s, scientists believed hunger was solely under gastrointestinal control; however, the hypothalamus and brainstem gained recognition as major contributors in the role of feeding (Kennedy 1953). Early studies describe the hypothalamus as having a main ‘feeding’ center in the lateral hypothalamus and a main ‘satiety’ center in the ventromedial hypothalamus (Anand & Brobeck 1951; Teitelbaum & Stellar 1954; Mayer & Thomas 1967), though subsequent research has demonstrated that multiple areas of the brain, including areas within the hypothalamus play key roles in the regulation of feeding and body weight. One area of the hypothalamus shown to play a key role in the regulation of food intake is the arcuate nucleus of the hypothalamus (ARC). The ARC has a high number of hormonal and neuropeptide receptors

and many of them affect feeding such as opioids, orexins, melanin-concentrating hormone, galanin-like peptides, galanin, and many more.

One important family of ARC neuropeptides that play a key role in regulating feeding are the melanocortins. The melanocortins are a family of neuropeptides produced by the *proopiomelanocortin* gene or *POMC*. Once created the POMC neuropeptide is broken down from its preprohormone precursor to physiologically active substances such as adrenocorticotrophic hormone (ACTH),  $\alpha$ ,  $\beta$ , and  $\gamma$  melanocyte-stimulating hormone (MSH), and  $\beta$ -endorphin (Mountjoy et al 1992; Palkovits et al 1987) as seen in Figure 1 (Cone 2006).



**Figure 1. Breakdown of melanocortin neuropeptides from its original state as a preprohormone**

POMC preprohormone is broken down from its preprohormone precursor to N-terminal, adrenocorticotrophic hormone (ACTH), and  $\beta$ -lipotropin (LPH) which are then broken down to create  $\alpha$ ,  $\beta$ , and  $\gamma$  melanocyte-stimulating hormone (MSH), corticotrophin-like intermediate peptide (CLIP),  $\gamma$ -LPH, and  $\beta$ -endorphin (Cone 2006).

The MSHs are commonly referred to as the melanocortins.  $\alpha$ -MSH is considered to be the most physiologically relevant melanocyte-stimulating hormone in the CNS because of its anorexigenic effects (decreases feeding); however,  $\beta$  and  $\gamma$ -MSH also been shown to have some physiological significance (Gantz et al 1999). Intraventricular injection of  $\alpha$ -MSH is known to cause decreased food intake, increase energy expenditure, and chronically can cause cachexia, or


extreme weight loss and malnourishment (Panskepp et al 1976; Fan et al 1997). A second set of neurons in the hypothalamus expresses agouti-related protein (AgRP), which is an endogenous antagonist of melanocortin receptors. AgRP acutely increases food intake, decrease energy expenditure, and chronically increases body weight (Fan et al 1997; Huszar et al 1997). AgRP is an antagonist to the melanocortins (Corander et al 2011), but can also act as an inverse agonist. This suggests that it not only blocks the receptor, but can cause the opposite effect, in this case, increased feeding (Haskell-Luevano & Monck 2001; Nijenhuis et al 2001). ACTH is produced in response to stress and has implications in grooming and sexual function. It is produced in the pituitary gland and mainly affects melanocortin receptors at its site of production as well as the adrenal cortex.  $\beta$ -endorphin is an endogenous opioid that has many functions, one being that it stimulates food intake through its receptors in the ARC and other places (Appleyard et al 2003).

There are five known G-protein coupled receptors that react with MSHs, melanocortin-1 receptor (MC1R) through melanocortin-5 receptor (MC5R) (Griffon et al 1994; Labbe et al 1994). MC3R and MC4R are the only two receptors present in the central nervous system (CNS) and therefore are the main focus of study in neurobiology (Mountjoy et al 1994; Roselli-Reh fuss et al 1993; Gantz et al 1993; Chhaklani et al 1996). MC4R is considered the primary MCR involved in body weight control because of its high binding affinity with  $\alpha$ -MSH and resulting strong physiological changes (Gantz et al 1993). MC4R plays a major role in energy homeostasis via food consumption control, energy expenditure, changes in sympathetic nervous system (SNS) activity. MC4R null mice are hyperphagic, gain weight, and develop insulin-resistance induced diabetes (Gantz & Fong 2002; Sutton et al 2006; Huszar et al 1997; Garza et al 2008). Melanocortin 4 deficiency is the largest monogenic cause for obesity in humans (Krude et al 1998; Farooqi et al 2000; Yaswen 1999). Though MC3R plays a role in body weight regulation,

the exact role is less clear. MC3R is involved in energy homeostasis via the manipulation of energy metabolism, or the fat-to-mass ratio. MC3R null mice do not increase food intake, but have a higher fat to mass body ratio than its wild-type counterparts. Research suggests this is caused by a change in metabolism due in large part to decreases in locomotor activity (Sutton et al 2006; Butler et al 2000; Chen et al 2000). Although MC3R has binding affinity with  $\alpha$ ,  $\beta$  and,  $\gamma$ -MSH, it has a lack of unique agonists/antagonists that exclusively bind to the MC3R which has made studying its effects difficult. Many still question the importance of MC3R due to confounding research (Lee et al 2008; Fan et al 1997). Recent papers, however, show that MC3R does in fact effect feeding, but the mechanism is still unknown (Marks et al 2006; Irani et al 2011).

Among the many neuronal subtypes in the ARC, two populations of neurons have been shown to play an important role in feeding, the first expressing proopiomelanocortin (POMC) and a second set of neurons expressing agouti-related peptide (AgRP) and neuropeptide Y (NPY). POMC neurons are potent anorexigenic stimulators while AgRP/NPY neurons are potent orexigenic stimulators (increase feeding) (Huzsar et al 1997; Fan et al 1997; Bulter et al 2000). Recent DREADD and optogenetic technologies have shown that stimulation of POMC neurons decreases food intake and body weight in the presence of only melanocortins and no other neuropeptide (Aponte et al 2011). Stimulation of the AgRP/NPY neurons acutely and dramatically increases food intake, decrease energy expenditure, and chronically increases body weight (Aponte et al 2011). Inhibition of AgRP neurons decreases food intake to below baseline standards independent of melanocortin stimulation suggesting AgRP is both 'necessary and sufficient' for feeding behavior (Krashes et al 2011). POMC and AgRP/NPY neurons share

many of the same projections as seen in Figure 2 (Cone 2005). This allows these two opposing systems to have control on each other.



**Figure 2. Projections of POMC and AgRP neurons throughout the rat brain**

POMC and AgRP neurons both project to the central nucleus of the amygdala, bed nucleus of the stria terminalis, lateral hypothalamus, and paraventricular nucleus of the hypothalamus. POMC exclusively projects to the dorsal motor nucleus of the vagus, reticular nucleus, nucleus tractus solitaries, and lateral paracrachial nucleus (Cone 2005).

Other hormones that interact with the homeostatic pathways to affect feeding and body weight are leptin, insulin, and ghrelin. Leptin is a hormone that is largely made by white adipose tissue, and it decreases with hunger, increases with satiety, and inhibits feeding via receptors in the ARC (Frederich et al 1995; Maffei et al 1995; Zhang et al 1994; Halaas et al 1995; Elmquist et al 1998). Insulin increases with blood glucose levels (Polonsky et al 1988), and causes hypophagia and weight loss within the CNS (McGowen et al 1992). Another peptide, ghrelin, has orexigenic effects by activating AgRP/NPY neurons in the ARC while suppressing POMC neural activity causing an overall increase in feeding and body weight (Seoane et al 2003;

Cowley et al 2003; Wren 2000). Although, there is no one cause for food consumption, the melanocortins and the peptides that affect them play a vital role in feeding. Furthermore, more recent studies focus on how the ‘reward pathway’ contributes to rewarding aspects of feeding.

### *1.2 Mesolimbic dopamine pathway*

There are certain areas within the brain that aid in motivation, learning, and pleasure. These circuits are responsible for the hedonics, or pleasure, of food intake without affecting the biological necessity of it. This occurs by changing the body’s response to salient environmental stimuli causing food intake during a time of food availability rather than for energy needs. This can result in a pleasurable experience. Evolutionarily speaking, without these pathways, animals with full energy stores would not always eat when food was available, and once food availability ran out, starvation could occur. One of the major hormones responsible for hedonic feeding is dopamine. One of its many neuronal projections extends from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and in combination with other projections is known as the mesolimbic dopamine (DA) system.

Researchers unknowingly began looking into this ‘reward’ area of brain while researching the cause for drug addiction. Drugs of abuse hijack these pathways which can be evolutionarily assumed to be useful when finding food or water. Dr. Roy A. Wise was one of the original researchers to focus his attention on the addiction phenomena. It was found that dopamine was important for brain self-stimulation (Yeomans 1979), and that positive drug self-administration regions of the midbrain overlapped with areas with a high density of dopaminergic cell bodies, specifically in the VTA and substantia nigra (Corbett & Wise 1980; Bozarth & Wise 1981; Wise 1982). At this time dopamine was the neurotransmitter believed to cause these addictions (Wise 1982). Studies confirmed in rats and humans that dopamine related to addiction and drugs of



abuse are found in the mesolimbic DA pathway, specifically from the VTA projecting to the ventral striatum, which includes the NAc (Di Chiara & Imperato 1988; Koob 1992; McBride et al 1999; Volkow et al 2004). Although, the VTA and NAc are often focused on, there are many other areas involved in this system; these include the dorsal striatum (caudate putamen- CPU), prefrontal cortex, and the amygdala. Research shows that it is the neurotransmitter dopamine in the NAc that causes the behavior to seek the drug, or the reward, and that without dopamine, its receptor, or its neurons, the self-administration or seeking behavior disappears (Ikemoto et al 1997; Roberts & Koob 1982). The result of increased dopamine levels from drugs of abuse typically decreases dopamine-2 (D2) receptors (Volkow et al 2002). It is assumed that this occurs as a reaction to an overabundance of dopamine; however, at this point it then requires more dopamine, i.e. more drugs of abuse, to receive the same dopaminergic effect of a smaller number of receptors. This phenomenon is thought to play a role in tolerance and addiction. This is shown in self-administration studies where mice progressively increase the amount of cocaine with similar resulting dopamine output (Ahmed et al 2002). The mechanisms by which dopamine is increased depends of the specific drug of abuse (Ritz et al 1987).

Dopamine is often considered the major component of the mesolimbic DA system, however, other transmitters play key roles in regulating the overall activity of this system. Glutamate plays an important role in these pathways with afferent projections from areas such as the hippocampus (O'Donnell & Grace 1995). GABA and endogenous opioids also affect the activity of this system and compose a feedback loop within the reward pathway (Trigo et al 2010). In addition, acetylcholine (ACh), which has interneurons in the NAc and various other projections throughout the system, is also an important regulator of the mesolimbic DA pathways

(Mark et al 2011). The mesolimbic dopamine pathway has been studied for decades and is still not completely understood.

### *1.3 Mesolimbic Dopamine System and Feeding*

Dopamine is an important neurotransmitter with a wide range of physiological functions including motivation, reward, and reinforcement, learning and memory, and motor control. Conditions associated with abnormal dopamine show changes in feeding and body weight. For example, dopamine-deficient (DD) mice are hypoactive, aphagic, and adipsic and will starve to death without help (Zhou & Palmiter 1996). Certain atypical antipsychotics are dopamine-2 (D2) receptor antagonists and are known to cause increased weight gain (Baptista et al 1990). D2 density has also been shown to be inversely proportional to the weight of obese patients suggesting a potential role of D2 receptors in development of obesity (Wang et al 2002). One study shows clozapine, a partial dopamine receptor antagonist, increases food intake in rats, and a D2 receptor agonist reverses it (Kaur & Kulkarni 2002). Parkinsons disease is characterized by dopamine cell death in the substantia nigra and its patients have lower body weight than their healthy counterparts (Beyer et al 1995). Patients that are given more levodopa treatments, a dopamine precursor, have a larger amount of weight loss suggesting the medication may be responsible (Bachmann et al 2009).

As humans, we have the tendency to ‘finish our plate’ of food past the necessary need for energy balance (Jansen et al 2003; Weingarten 1983). This alone suggests that some other control systems other than basic energy needs are involved in feeding. Despite the important role of the mesolimbic DA pathways in drugs of abuse, it is thought that these pathways were originally designed to respond to naturally rewarding substances. Food and water increase dopamine in the NAc and VTA similar to, but less than, drugs of abuse. This suggests that it is

the overall reward that dopamine triggers, and is not specific to drugs (Hernandez & Hoebel 1988; Yoshida et al 1992). It has been shown that ‘addicted’ animals prefer highly-intense sugar over cocaine suggesting that it is possible that food has the potency to be just as addicting as any drug of abuse (Lenoir et al 2007). The mechanism for overeating shows similarities to drugs of abuse. Obese patients have decreased D2 receptors similar to the decrease in drug addicts (Wang et al 2001). In addition, patients who have undergone gastric bypass surgery have upregulated D2 receptors, in theory, to try to restore the dopamine levels to previous pre-surgery ‘reward’ levels (Steele et al 2010). Similar findings have been shown in obese rats that are then placed on a restricted feeding diet resulting in weight loss (Hamdi et al 1992). Rats on high fat diets are less likely to experience ‘reward’ due to decreased self-stimulation, and presumably decreased D2 receptors. When the D2 receptors are knocked down, feeding dramatically increases supporting the theory that dopamine is what is responsible for giving the ‘rewarding’ feeling. It is also possible that without these receptors animals will consume drugs or food to try to receive the same dopamine stimulation. In evolution theory, these reward pathways were likely put in place for species necessities such as food, water, and reproduction; however, drugs of abuse use these pathways to cause their own rewarding effects. Although the reward pathway can independently affect feeding, its interactions with other pathways are just as important.

#### *1.4 Reward and the dorsal striatum*

Although the ventral striatum/NAc gets a lot of attention in the mesolimbic DA pathway, the dorsal striatum is a key target for DA output as well. The dorsal striatum which is composed of the caudate putamen (CPu) is another key area of interest. Its inputs include the cortex, thalamus, and the mesolimbic DA neurons which are similar areas to the ventral striatum pathways (VTA to NAc). The NAc has dopaminergic innervations via the VTA whereas the CPu

has dopaminergic innervations via the substantia nigra. These DA neurons have been characteristically associated with motor function and their deficiency with the neuromuscular disorder Parkinsons Disease (PD) (Chase et al 1996). PD patients have symptoms that include hypophagia; however, this is attributed to the associated dysphagia and depression. The CPU's effects on reward were shown as far back as the 80s (Hikosaka et al 1989). Research also associates the CPU with learning, which is an important component of reward (Jog et al 1999; Packard & White 1990).

While the CPU has known effects in drugs, learning, and PD, recent research has indicated importance in feeding. Szczyпка et al restored DA in dopamine deficient (DD)-mice only in the CPU. This resulted in mice regaining the motivation to eat and ability to maintain an adequate sustainable body weight which is not possible in DD-mice (Szczyпка et al 2001). In addition, it has been shown that dopamine increases in relation to drinking in rats in the NAc as well as the CPU (Young et al 1992). This suggests that it is possible that motivation and learning, which are components of addiction and rewarding behavior, to eat or drink is not solely contained within the ventral striatum and its efferent projections from the VTA. The 'reward' circuits may lie within the ventral as well as dorsal striatum. This also suggests that the hypophagia associated with Parkinsons may be due to the dopamine or melanocortin neuronal changes in the dorsal striatum.

### *1.5 Mesolimbic and homeostatic feeding pathway interactions*


While most research has focused on the role of homeostatic or hedonic pathways of food intake control independent of each other, it is clear that there are important interactions between these pathways. Although this is thought of as a new area of study, researchers have been investigating this connection for decades. It has been shown that animals will lever-press for

heroin injections into the hypothalamus, a role traditionally thought of in the mesolimbic DA pathway (Gerber et al 1981). In addition, excitation of the lateral hypothalamus via the medial forebrain bundle causes the same dopamine release in the NAc independent of the VTA (Hernandez & Hoebel 1988; 1988). By 1992 evidence of a direct link between the NAc shell and the lateral hypothalamus was well documented (Heimer et al 1991; Zahm & Brog 1992), and it was known that the NAc has role in feeding behavior (Salamone 1994).

The mechanism of how these two pathways interact and how they affect food intake is still developing. Rada et al found glutamate levels in the lateral hypothalamus and the NAc changed in response to food intake suggesting not only do these areas share pathways, but that they also aid in the control of feeding (Rada et al 1997). Also, NAc-induced feeding could be attenuated with GABA agonist injections into the lateral hypothalamus (Maldonado-Irizarry et al 1995). In addition to the NAc the hypothalamus has been shown to have connections to the VTA. Retrograde tracing injected into the lateral hypothalamus shows strong afferents in the VTA, NAc shell, and many other areas (Duva et al 2005). Orexin, an orexigenic neuropeptide, has been shown to have projections from the lateral hypothalamus to the VTA (Fadel & Deutch 2002). Also, orexin injected into the VTA causes firing, and orexin projections to the VTA are required for morphine-related conditioned place preference (Korotkova et al 2003; Narita et al 2006). Recent studies have shown that orexin signaling in the VTA is required for opioid-induced food intake in the NAc suggesting not only a connection between the lateral hypothalamus and the VTA, but a possible relationship to rewarding food intake (Zheng et al 2007). In addition to orexin, melanin-concentrating hormone (MCH), another orexigenic neuropeptide, also has projections from the lateral hypothalamus to the mesolimbic DA pathway (Bittencourt et al 1992) with many receptors in the VTA and NAc specifically (Hervieu et al 2000). Smith et al

showed that MCH-1 receptor knockout mice, characterized by hyperactivity and hypophagia, have increased dopamine in the VTA as well as the NAc further suggesting a functional association between these two areas (Smith et al 2005).

In addition to the neuronal connection between the VTA, NAc, and lateral hypothalamus, dopamine neurons in the VTA have receptors for important feeding relevant hormones similar to the ARC. Leptin, insulin, and ghrelin not only affect feeding via the homeostatic pathways, but they also have effects on dopamine within the mesolimbic DA system to affect feeding. Leptin when injected in the ventricles decreases feeding-evoked dopamine release in the NAc (Krugel et al 2003). Insulin receptors have also been found in the VTA dopaminergic neurons, (Pardini et al 2006; Figlewicz et al 2003) and intraventricular insulin was shown to reduce the self-stimulation of sucrose (Figlewicz et al 2006). Ghrelin increases dopamine firing in the VTA and decreases inhibitory firing and as a result causes food intake (Abizaid et al 2006; Naleid et al 2005). Figure 3 created by RD Palmiter shows the different hormones and neuropeptides that have been shown to affect dopaminergic neurons in the VTA (Palmiter 2001).



**Figure 3. Neuropeptides that affect dopamine neurons**

GABA, leptin, and insulin have been shown to have inhibitory receptors on DA neurons in the VTA, while ghrelin, orexin, and glutamate have been shown to have excitatory receptors in the VTA (Palmiter 2001).

### *1.6 Mesolimbic dopamine pathway and melanocortin interactions*

In addition to leptin's, insulin's, and ghrelin's interaction with dopaminergic pathways, there is also evidence indicating melanocortin involvement within the VTA and the mesolimbic DA system. MC4R mRNA has been found in the VTA, NAc, and CPu, and the MC3R has been found extensively in the VTA (Kishi et al 2003; Liu et al 2003; Rosseli-Reh fuss et al 1993).  $\alpha$ -MSH injections in the VTA have been shown to increase dopamine turnover and grooming in rats, a typically melanocortin characterization, via the MC4R (Klusa et al 1998; Lindblom et al 2001). In addition,  $\gamma_1$ -MSH injections into the VTA increase dopamine and its metabolites in the NAc (Jansone et al 2004). In 1986, it was shown that  $\alpha$ -MSH injected into the ventricles or substantia nigra causes changes in dopamine in the caudate putamen (Torre & Celis 1986). Davis et al showed that centrally administered AgRP, a melanocortin antagonist, increased dopamine firing in the midbrain with associated dopamine turnover in the prefrontal cortex, a known projection site of mesolimbic DA neurons (Davis et al 2011).


Many studies looking at drugs of abuse have also linked melanocortins with the mesolimbic DA pathway. Alvaro et al showed that morphine down-regulated MC4R in the NAc as well as the CPu (1996). An exogenous melanocortin receptor agonist was shown to cause an increase in rewarding effects of amphetamines in the lateral hypothalamus (Cabeza de Vaca et al 2002). Similarly, an exogenous melanocortin receptor antagonist caused a decreased in rewarding effects of cocaine in the NAc (Hsu et al 2005, 2009). Here, the term 'rewarding effects' refers to the perceived reward received from drugs of abuse and the reinforcing motivation to seek said drug. In addition, POMC mRNA was shown to decrease in response to morphine (Bronstein et al 1990). This building research shows that the melanocortins interact with mesolimbic DA system to affect responses to various drugs of abuse.

It seems clear that the melanocortins interact with the mesolimbic DA pathway for some behaviors; however, there is little research referring to this interaction and its direct effects on feeding. Xenakis and Sclafani showed that a dopamine receptor antagonist suppressed sucrose preference (1981). In addition, melanocortin agonists or NPY antagonists can inhibit opioid induced feeding in the NAc (Zheng et al 2010). These findings suggest that melanocortins and AgRP/NPY have projections as well as possible feeding related interactions with the NAc. Figure 4 shows the theorized mechanism for how the homeostatic pathway interacts with the reward pathway (Palmiter 2007). In addition, recent studies have shown that melanocortin agonists injected directly into the VTA cause a decrease in food intake (Roseberry, personal communication), however, more information is required to fully understand the role melanocortins play in the mesolimbic DA system to affect feeding.

### *1.7 Research Goals*

I will create short-hairpin RNAs (shRNAs) that target MC3R and MC4R separately. These shRNAs will be used in *in vitro* co-transfections with their target receptors to examine knockdown efficiencies of each shRNA.





**Figure 4. A sample of the known relationships between the homeostatic and reward pathways**

Leptin and insulin act on the ARC on POMC/CART and AgRP/NPY neurons to decrease feeding while ghrelin acts on these areas to increase feeding in the homeostatic pathway. POMC/CART and AgRP/NPY neurons both have projections to many similar locations including the paraventricular nucleus and the lateral hypothalamus. Orexin neurons project from the lateral hypothalamus to the VTA of the reward pathway. The reward pathway consists of DA and GABA projections to the NAc. Leptin, insulin, and ghrelin also can act in the VTA (Palmiter 2007).

## 2 METHODS/EXPERIMENTAL PROTOCOL


### 2.1 Creation of shRNA targeting the MC3R and MC4R

Three 24 base pair short hairpin RNAs (shRNAs) were designed to target the MC3R and three to target the MC4R. The shRNAs were created using previously developed methods (Hommel et al 2003) and BLASTed to ensure specificity. The sequences of each shRNA can be seen in Table 1.

**Table 1. Targeted mRNA sequences used to create pAAV short-hairpins**


	mRNA sequence
MC3R	
sh1	TCCCTGACCTTGGAGGACCAATTC
sh2	TGCGGCGTGATGTTTCATCGTCTAC
sh3	ACACGGCGCACTTCAACACCTACC
MC4R	
sh1	TCATAAGCCTGTTGGAGAACATTC
sh2	GCAGTGGACAGGTATTTCACTATC
sh3	CTACATCTCTTGTCCTCAGAATCC
CONTROL	
	CGGAATTTAGAAACCCGGCTCCAA

The control mRNA sequence was created and tested previously and has no known target (Hommel et al 2003). Effective shRNAs were created by using a 10 nucleotide hairpin loop (CTTCCTGTCA) to join the antisense shRNA to the corresponding sense strand sequence as shown in Figure 5. The shRNAs were cloned into a pAAV vector using standard methods to be used for future creation of adeno-associated viruses (AAVs). The AAV shRNA constructs will express the shRNAs under control of the mU6 promoter, and also contain GFP under the control of the CMV promoter to allow for high level expression of both the shRNA and the marker GFP as seen in Figure 6.



**Figure 5. Schematic of short-hairpin creation used in RNAi**

The sense strand is the 24 bp target RNA sequence followed by a hairpin loop, the antisense strand, followed by a terminating poly T tail.



**Figure 6. Design of AAV shRNAs**

Image shows that GFP is controlled by a CMV promoter while the shRNA is controlled by a mU6 promoter

## 2.2 *ptdTomato-MC3/4R* creation

Gene fusion constructs were created containing the MC3R or MC4R cDNA fused to the C-terminus of the tdTomato fluorescent protein in the ptdTomato-C1 vector (Clontech Laboratories) using EcoRI and XbaI restriction enzymes and standard molecular biology techniques. These fusion constructs will be used for *in vitro* studies to test shRNA ability to suppress tdTomatoMC3/4R. The MC4R was received as a generous gift from Dr. Xin-Yun Lu, University of Texas Health Science Center at San Antonio, and the MC3R was synthesized *de novo* by GenScript. The MC3/4R portion of the tdTomatoMC3/4R fusion constructs are not in frame so no mature MC3/4R protein is attached to the C-terminus of the functional tdTomato protein; however, there is full mRNA expression which allows for targeting of the tdTomato MC3/4 R mRNA by the shRNAs.

### 2.3 *shRNA testing in vitro*

The pAAV-shRNA constructs, as described in 2.1, were co-transfected with the tdTomatoMC3/4R fusion constructs, as described in 2.2, into HEK-293 cells to determine the most effective shRNA to be used for *in vivo* experimentation. The pAAV-shRNA (5 µg) and ptdTomatoMC3/4R (1 µg) DNAs were co-transfected into HEK-293 cells using standard calcium-phosphate methods (Roseberry et al 2001). Each shRNA *in vitro* experiment was

**Table 2. Experimental co-transfections into HEK-293 cells**

The pAAV-shRNA co-transfected with its target receptor, as seen on the left, are used to test knockdown effectiveness, while the pAAV-shRNA co-transfected with a control target, as seen on the right, are used to test knockdown specificity of the shRNA.

ptdTomatoMC3R + pAAV-MC3Rsh1	ptdTomatoMC3R + pAAV-MC4Rsh1
ptdTomatoMC3R + pAAV-MC3Rsh2	ptdTomatoMC3R + pAAV-MC4Rsh2
ptdTomatoMC3R + pAAV-MC3Rsh3	ptdTomatoMC3R + pAAV-MC4Rsh3
ptdTomatoMC3R + pAAV-shControl	ptdTomatoMC3R + pAAV
ptdTomatoMC3R + pAAV	ptdTomatoMC3R + pAAV-MC3Rsh2
ptdTomato-MC4R + pAAV-MC4Rsh1	ptdTomatoMC4R + pAAV-MC3Rsh1
ptdTomato-MC4R + pAAV-MC4Rsh2	ptdTomatoMC4R + pAAV-MC3Rsh2
ptdTomato-MC4R + pAAV-MC4Rsh3	ptdTomatoMC4R + pAAV-MC3Rsh3
ptdTomato-MC4R + pAAV-shControl	ptdTomatoMC4R + pAAV
ptdTomato-MC4R + pAAV	ptdTomatoMC4R + pAAV-MC4Rsh2

performed 3-4 times and included an empty pAAV and a pAAV control shRNA as internal controls. Cells were plated to polylysine covered cover-slips one day post-transfection and were then fixed with methanol/acetone and mounted to slides three days post-transfection.

As seen in Table 2, specificity was tested by completing co-transfections with MC3RshRNAs with tdTomatoMC4R and MC4RshRNAs with the tdTomatoMC4R. These experiments also had an empty pAAV vector as a negative control and a receptor-specific short-hairpin as a positive control.


## 2.4 Data Analysis and Statistics

Slides containing the transfected cells were viewed using a Nikon E800 upright microscope. Slides were randomly sampled and approximately ten images were taken per transfection. Image acquisition parameters were the same for all treatments in each individual experiment. Images were quantified using ImageJ software (National Institute of Health, Bethesda, MD). Positive cells were selected using brightness thresholds and cell counter functions, and all measurements were confirmed by experimenter. Paired t-tests were used to compare the number of GFP and tdTomato positive cells for each treatment. One-way ANOVA with Holm-Sidak post-hoc tests were used to compare the level of tdTomato knockdown observed for each pAAV construct.

## 3 RESULTS


Three pAAV-shRNAs were created targeting the MC3R or MC4R, and each shRNA was tested *in vitro* for its effectiveness in knocking down MC3R or MC4R. The knockdown was measured by comparing the number of cells expressing tdTomato to the number of cells expressing GFP, which is expressed by pAAV, and is used to mark all transfected cells. The MC3/4Rs are fused to the C-terminus of the tdTomato and will produce one mRNA that will be targeted by the shRNAs. In a successful knockdown, the shRNAs, co-expressed with GFP, will knockdown the tdTomatoMC3/4R fusion reducing tdTomato fluorescence. In an unsuccessful knockdown, both GFP and tdTomato fluorescence will be present. As mentioned previously, the MC3/4R is not in frame with the tdTomato, and no functional receptor protein will be created; however, these experiments will remain unaffected because the tdTomato fluorescent protein will still be expressed. In each experiment, an empty pAAV vector and a scrambled control short-hairpin were co-transfected with each tdTomato-receptor as negative controls.

Initially, the MC3R shRNAs were tested (Figure 7-9). The three shRNAs targeting MC3R significantly decreased tdTomatoMC3R expression (Figure 7-9) to varying degrees. MC3Rsh2 had the greatest tdTomato knockdown with 85.5% followed by MC3Rsh3 with 78.9% and MC3Rsh1 with 70.8% (Figure 9). Finally, as expected, the control shRNA had no effect on tdTomatoMC3R expression (Figure 7-9).




**Figure 7. Sample images showing effectiveness of the MC3R shRNAs on tdTomatoMC3R expression**

Green cells indicate GFP expressed by the pAAV-shRNA, and red cells indicate tdTomatoMC3R expression. A decrease in the number of red cells as compared to green cells is indicative of the ability of the shRNA to block expression of the tdTomato-MC3R.



**Figure 8. MC3R shRNAs decrease expression of tdTomatoMC3R in HEK-293 cells**

Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following co-transfection of the shRNAs with the tdTomatoMC3R. 'Empty' refers to pAAV vector with no shRNA. \* $p < 0.05$ ;  $n=4$ .




**Figure 9. Extent of knockdown of the tdTomatoMC3R by the MC3R shRNAs**

All three shRNAs decreased expression of tdTomatoMC3R compared to empty pAAV and shControl. \* $p < 0.001$  compared to both empty pAAV and shControl;  $n=4$ .




Next, MC4R shRNAs were tested to investigate their ability to block expression of the tdTomatoMC4R. As with the MC3R, all MC4R shRNAs decreased tdTomato expression to varying degrees (Figure 10-12). MC4Rsh3 was the most effective (90.4% knockdown) followed by MC4Rsh2 (88.6% knockdown) and MC4Rsh1 (73.7% knockdown). Finally, similar to MC3R, the control shRNA had no effect on expression of the tdTomatoMC4R protein (Figure 10-12).




**Figure 10. Sample images showing effectiveness of the MC4R shRNAs on tdTomatoMC4R expression**

Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato expression. A decrease in the number of red cells as compared to the green cells is indicative of the ability of the shRNA to block expression of the tdTomatoMC4R.



**Figure 11. MC4R shRNAs decrease expression of tdTomatoMC4R in HEK-293 cells**


Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following co-transfection of the shRNAs with the tdTomatoMC4R. 'Empty' refers to pAAV vector with no shRNA. \*  $p < 0.05$ ;  $n=3$ .



**Figure 12. Extent of knockdown of the tdTomatoMC4R by the MC4R shRNAs**


All three shRNAs decreased expression of tdTomatoMC4R compared to empty pAAV and shControl. \*  $p < 0.001$  compared to both empty pAAV and shControl;  $n=3$ .

Experiments were also performed to test the specificity of the shRNAs. In these experiments the ability of the MC3R shRNAs to affect expression of the tdTomatoMC4R was tested, as was the ability of the MC4R shRNAs to affect expression of the tdTomatoMC3R. As shown by Figures 13-16, none of the shRNAs affected expression of the non-targeted receptor. This suggests that all six of the shRNAs are specific to their own receptor. Overall, pAAV-MC3Rsh2 and pAAV-MC4Rsh3 had the greatest tdTomato knockdown, and therefore will be used for future *in vivo* experimentation.




**Figure 13. Sample images showing no MC3Rsh2 effect on tdTomatoMC4R**

Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato expression. Images suggest MC3Rsh2 has no knockdown on tdTomatoMC4R and is specific to its target receptor, MC3R.




**Figure 14. MC3R shRNAs do not affect expression of tdTomatoMC4R**

Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following co-transfection of the MC3R shRNAs with the tdTomato-MC4R. ‘Empty’ refers to pAAV vector with no shRNA. pAAV-MC4Rsh2 was included as a positive control; n=2.



**Figure 15. Sample images showing no MC4Rsh3 effect on tdTomatoMC3R**

Green indicates GFP expressed by the pAAV-shRNA construct, and red indicates tdTomato expression. Images suggest MC4Rsh3 has no knockdown on tdTomatoMC3R and is specific to its target receptor, MC4R.



**Figure 16. MC4R shRNAs do not affect expression of tdTomatoMC3R**

Total number of GFP-positive (Light grey) and tdTomato-positive cells (Dark grey) following co-transfection of the MC4R shRNAs with the tdTomato-MC3R. ‘Empty’ refers to pAAV vector with no shRNA.. pAAV-MC3Rsh2 was included a positive control; n=2.

#### 4 DISCUSSION

The mesolimbic DA pathway has been shown to have physiological interactions with melanocortins (Klusa et al 1998; Alvaro et al 1996; Bronstein et al 1990) as well as melanocortin receptor mRNA (Roselli-Reh fuss et al 1993; Kishi et al 2003; Liu et al 2003). This system has also been shown to affect feeding via similar mechanisms (Maldonado-Irizarry et al 1995; Wang et al 2001; Salamone 1994). Therefore, this pathway acts as a place of interest for better understanding melanocortin’s role in feeding behaviors. Previous studies have used a variety of techniques (MC4R-null animals, RNAi , cell-specific receptor knockouts) to show that melanocortins affect food intake within the hypothalamus (Huszar et al 1997; Balthasar et al 2005; Garza et al 2008). None of these relatively new techniques, however, have been used to understand whether melanocortins affect feeding through the mesolimbic DA pathway.

In these studies, shRNAs targeting the MC3R and MC4R were designed, tested, and resulting in varying degrees of successful knockdown. The shRNAs with the highest knockdown were pAAV-MC3Rsh2 with 85.5% knockdown (Figure 9) and pAAV-MC4Rsh3 with 90.4% knockdown (Figure 12), thus making them the chosen shRNAs for future use in rats *in vivo*.

pAAV-MC4Rsh1 is the only short-hairpin created that could be used in rat as well as mouse animals models because of a shared coding region, *acacggcccatttcaacacctacc*, found at base pair 167 in the rat. The option of using two different animal models to investigate melanocortin's role in mesolimbic DA pathways could add to the evidence of a conserved pathway between species.

Previous studies have found that the U6 promoter *in vitro* knockdown was found to be ~80% (Makinen et al 2006). Another similar study using the U6 promoter to target MC4R *in vitro* found their knockdown ranged from 86 to 94% over three different short-hairpins (Garza et al 2008). Therefore, the 85.4 and 90.4% knockdown for MC3R and MC4R respectively seems to be an appropriate knockdown level *in vitro*. Therefore, these shRNAs would be suitable candidates for future *in vivo* testing. The expression of GFP and shRNA is under the control of different promoter regions (U6 expresses shRNA; CMV expresses GFP), and effective knockdown still occurs as seen in current and previous studies using similar shRNA constructs (Hommel et al 2003).

The shRNA constructs have the potential to answer many questions about the connections between melanocortins and the mesolimbic DA pathways, and their roles in a number of behaviors including food intake. Based on important roles of both the mesolimbic DA system and melanocortins in feeding, a likely first set of experiments would be to examine whether MC3R or MC4Rs in the mesolimbic DA system play a role in feeding. MC3R mRNA is

found in high levels in the VTA, while MC4R mRNA is found in low levels in the VTA, moderate levels in the NAc, and high levels in the CPu (Roselli-Reh fuss et al 1993; Kishi et al 2003; Liu et al 2003). In addition to the mRNA, it is known that melanocortins have functional or physiological effects within the same regions (Klusa et al 1998; Lindblom et al 2001; Jansone et al 2004; Alvaro et al 1996; Hsu et al 2005, 2009). Therefore, the VTA, NAc, and CPu are all regions of interest that could be examined. While, it is known that dopamine can affect baseline feeding, there is evidence to suggest that it affects rewarding feeding as well. Highly palatable food causes increased *c fos* in the VTA (Park & Carr 1998), and inactivation of the NAc causes increased preference for high-fat and high-sugar foods (Zhang & Kelley 1997). Thus, normal feeding as well as reward-related feeding, such as high fat and high sugar foods, are logical areas to be examined.

In addition to feeding-related studies, melanocortins have also been shown to have drug-related interactions in the mesolimbic DA system (Alvaro et al 1996; Hsu et al 2005; Bronstein et al 1990). Thus, melanocortin shRNAs could also be used to investigate drug-related behaviors, such as locomotion, conditioned place preference, and self-administration within the mesolimbic DA system.

There are multiple methods that could be used to investigate melanocortin effects within the mesolimbic DA system; however, RNA interference was the best possible for the questions addressed in this study. Genetic knockout animals, in which knockout either occurs throughout the brain or in specific cells, are often used to investigate similar questions. It is currently unknown, however, which neurons MC3/4Rs are located on, and thus is a disadvantage because it cannot be used to target overall regions, i.e. VTA. Another possible method could have been agonist or antagonist microinjections. Although this method can target specific regions, it is



limited by the number of microinjections allotted to one animal. This limits not only the length of the study (acute vs. chronic), but the varying types of behaviors that can be examined within one animal. RNA interference is not without downfall however. shRNAs are not likely to create 100% receptor knockdown. Therefore the full behavioral effects of that receptor cannot be seen. In these studies, the ability to target a specific area over a longer period of time was important, and thus RNA interference was chosen as the methodology.

In summary, these highly effective shRNAs can be used to target various regions of the mesolimbic DA pathway as well as to examine various behavioral effects within these regions. These studies will allow for investigation of melanocortin effects within the mesolimbic DA system and for further characterization of melanocortin function in respect to rewarding feeding on high-fat foods as well as high-sugar foods.

## REFERENCES

- Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, Roth RH, Sleeman MW, Picciotto MR, Tschop MH, Gao XB, Horvath TL. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. *J Clin Invest.* 2006; 116(12): 3229-39.
- Ahmed SH, Kenny PJ, Koob GF, Markou A. Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. *Nature Neuroscience.* 2002; 5: 625-6.
- Alvaro JD, Tatro JB, Quillan JM, Fogliano M, Eisenhard M, Lerner MR, Nestler EJ, Duman RS. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. *Mol. Pharmacol.* 1996; 50(3): 583-91.
- Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. *Yale J. Biol. Med.* 1951; 24: 123-40.
- Aponte Y, Atasoy D, Sternson SM. AgRP neurons are sufficient to orchestrate feeding behavior rapidly and without training. *Nat Neurosci.* 2011; 14(3): 351-5.
- Appleyard SM, Hayward M, Young JI, Butler AA, Cone RD, Rubinstein M, Low MJ. A role for the endogenous opioid beta-endorphin in energy homeostasis. *Endocrinology.* 2003; 144(5): 1753-60.
- Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. *Eur J Neurol.* 2009; 16(8): 895-901.
- Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, Christiansen LM, Edelstein E, Choi B, Boss O, Ashchkenasi C, Zhang CY, Mountjoy K, Kishi T, Elmquist JK, Lowell BB. Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell.* 2005; 123(3): 493-505.
- Baptista T, Hernandez L, Hoebel BG. Systemic sulpride increases dopamine metabolites in the lateral hypothalamus. *Pharmacol Biochem Behav.* 1990; 37: 227-9.
- Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, et al. The catabolic action of insulin in the brain is mediated by melanocortins. *J. Neurosci.* 2002; 22: 9048-52.
- Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients with Parkinson's disease. *J Am Diet Assoc.* 1995; 95(9): 979-83.
- Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. *J Comp Neurol.* 1992; 319: 218-245.
- Bozarth MA, Wise RA. Intracranial self-stimulation of morphine into the ventral tegmental area in rats. *Life Sci.* 1981; 28(5): 551-5.
- Bronstein DM, Przewlocki R, Akil H. Effects of morphine treatment on pro-opiomelanocortin systems in rat brain. *Brain Research.* 1990; 519: 102-11.
- Bulter AA, Kesterson RA, Khong T, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone R. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. *Endocrinology.* 2000; 141(9): 3518-21.
- Cabeza de Vaca S, Kim GY, Carr KD. The melanocortin agonist MTII augments the rewarding effect of amphetamine in ad-libitum-fed and food-restricted rats. *Psychopharmacology.* 2002; 161: 77-85.

- Carelli RM, Ijames SG, Crimling AJ. Evidence that separate neural circuits in the nucleus accumbens encode cocaine versus 'natural' (water and food) reward. *J. Neurosci.* 2000; 20: 4255-66.
- Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutaminergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. *Adv. Neurol.* 1996; 69: 497-501.
- Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan X-M, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, Macintyre DE, Chen HY, Van der Ploeg LHT. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. *Nat Genet.* 2000; 26: 97-102.
- Chen HY, Trumbauer ME, Chen AS, Weingarh DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feigner SD, Gaun XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, Qian. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. *Endocrinology.* 2004; 145: 2607-12.
- Chhajlani V, Muceniece R, Wikberg JE. Molecular cloning of a novel human melanocortin receptor. *Biochem Biophys Res Commun.* 1996; 218: 638.
- Cone RD. Anatomy and regulation of the central melanocortin system. *Nature Neuroscience.* 2005; 8(5): 571-8.
- Cone RD. Studies of the physiological function of the melanocortin system. *Endocrine Reviews.* 2006; 27(7): 736-49.
- Corander MP, Rimmington D, Challis BG, O'Rahilly S, Coll AP. Loss of agouti-related peptide does not significantly impact the phenotype of murine POMC deficiency. *Endocrinology.* 2011; 152(5): 1819-28.
- Corbett D, Wise RA. Intracranial self-stimulation in relation to the ascending dopaminergic systems of the midbrain: a moveable electrode mapping study. *Brain Research.* 1980; 285: 1-15.
- Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, et al. Leptin activates anorexigenic POMC neurons through a neuronal network in the arcuate nucleus. *Nature.* 2001; 411: 480-84.
- Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotony P, Fiedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuron.* 2003; 37: 649-61.
- Date Y, Shimbara Y, Koda S, Toshinai K, Ida T, Murakami N, Miyazato M, Kokame K, Ishizuka Y, Ishida Y, Kageyama H, Shioda S, Kangawa K, Nakazato M. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. *Cell Metab.* 2006; 4(4): 323-31.
- Davis JF, Choi DL, Shurdak JD, Krause EG, Fitzgerald MF, Lipton JW, Sakai RR, Benoit SC. Central melanocortins modulate mesocorticolimbic activity and food seeking behavior in the rat. *Physiol Behav.* 2011; 102(5): 491-5.
- Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V, Kenny CD, Christiansen LM, White RD, Edelstein EA, Coppari R, Balthasar N, Cowley MA, Chua S Jr, Elmquist JK, Lowell BB. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. *Neuron.* 2006; 49(2): 191-203.

- Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc. Natl. Acad. Sci. U.S.A.* 1988; 85: 5274-8.
- Duva MA, Tomkins EM, Moranda LM, Kaplan R, Sukhaseum A, Stanley BG. Origins of the lateral hypothalamic afferents associated with N-methyl-d-aspartic acid-eleicted eating studied using reverse microdialysis of NMDA and Fluorogold. *Neurosci Res.* 2005; 52(1): 95-106.
- Elmqvist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor mRNA isoforms in the rat brain. *J Comp Neurol.* 1998; 395(4): 535-47.
- Fadel J, Deutch AY. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. *Neuroscience.* 2002; 111: 379-87.
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. *Nature.* 1997; 385: 165-168.
- Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, O'Pahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. *J Clin. Invest.* 2000; 106: 271-279.
- Figlewicz DP, et al. Intraventricular insulin increases dopamine transporter mRNA in the rat VTA/substantia nigra. *Brain Res.* 1994; 644: 331-334.
- Figlewicz DP, Bennett J, Evans SB, Kaiyala K, Sipols AJ, Benoit SC. Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats. *Behav Neurosci.* 2004; 118(3): 479-87.
- Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG. Expression of receptors for insulin and leptin in ventral tegmental area/substantia nigra of the rat. *Brain Res.* 2003; 964: 107-15.
- Figlewicz DP, Higgins MS, Ng-Evans Sb, Havel PJ. Leptin reverses sucrose-conditioned place preference in food-restricted rats. *Physiol Behav.* 2001; 73(1-2): 229-34.
- Flegal KM, Carroll MD, Odgen CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. *JAMA.* 2010; 303(3): 235-41.
- Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. *Cell.* 2004; 116: 337-350.
- Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. *Nat Med.* 1995; 1(12): 1311-14.
- Fry J, Finley W. The prevalence and costs of obesity in the EU. *Proceedings of the Nutrition Society.* 2004; 64:987-1002.
- Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada Y. *J. Biol. Chem.* 1993; 268(11): 8246-50.
- Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada Y. Molecular cloning and characterization of the rat fifth melanocortin receptor. *Biophys Res Commun.* 1994; 200: 1214-20.
- Garza JC, Kim Chung Sub, Liu J, Zhang W, Lu X. Adeno-associated virus-mediated knockdown of melanocortin-4 receptor in the paraventricular nucleus of the hypothalamus promotes high-fat diet-induced hyperphagia and obesity. *Journal of Endocrinology.* 2008; 197(3): 471-482.
- Gerber GJ, Bozarth MA, Wise RA. Small-dose intravenous heroin facilitates hypothalamic self-stimulation without response suppression in rats. *Life Sci.* 1981; 28(8): 557-62.

- Glass MJ, Billington CJ, Levine AS. Opioid and food intake: distributed functional neural pathways? *Neuropeptides*. 1999; 33: 360-8.
- Goncalves, MAFV. Adeno-associated virus: from defective virus to effective vector. *Virology Journal*. 2005; 2(43): 1-17.
- Griffon N, Mignon V, Facchinetti P, Diaz J, Schwartz JC, Sokoloff P. Molecular cloning and characterization of the rat fifth melanocortin receptor. *Biochem Biophys Res Commun*. 1994; 200: 1007-14.
- Halaas JL, Gajiwala KS, Maffei M, Cogen SL, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science*. 1995; 269 (5223): 543-6.
- Hamdi A, Porter J, Prasad C. Decreased striatal D2 dopamine receptors in obese Zucker rats: changes during aging. *Brain Research*. 1992; 589: 338-40.
- Haskell-Luevano C, Monck EK. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. *Regul. Pept*. 2001; 99(1): 1-7.
- Haslam DW, James PT. Obesity. *The Lancet*. 2005; 366(9492): 1197-209.
- Hayward MD, Pintar JE, Low MJ. Selective reward deficit in mice lacking  $\beta$ -endorphins and enkaphalin. *J Neurosci*. 2002; 22(18):8251-8.
- Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. *Neuroscience*. 1991; 41: 89-125.
- Hernandez L, Hoebel BG. Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. *Physiology & Behavior*. 1988; 44(4-5): 599-606.
- Hernandez L, Hoebel BG. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. *Life Sci*. 1988; 42(18): 1705-12.
- Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, Leslie RA. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, *slc-1*, in the central nervous system of the rat. *Eur J Neurosci*. 2000; 12: 1194-216.
- Hikosaka O, Sakamoto M, Usui S. Functional properties of monkey caudate neurons. Activities related to expectation of target and reward. *J. Neurophysiol*. 1989; 61: 814-32.
- Hoebel BG. Hypothalamic self-stimulation and stimulation escape in relation to feeding and mating. *Fed Proc*. 1979; 38(11): 2454-61.
- Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ. Local gene knockdown in the brain using viral-mediated RNA interference. *Nat Med*. 2003; 9(12):1539-44.
- Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon JJ, Marinelli M, DiLeone RJ. Leptin receptor signaling in midbrain dopamine neurons regulates feeding. *Neuron*. 2006; 51(6): 801-10.
- Hsu R, Taylor JR, Newton SS, Alvaro JD, Haile C, Han G, Hruby VJ, Nestler EJ, Duman RS. Blockade of melanocortin transmission inhibits cocaine reward. *Eur J Neurosci*. 2005; 21(8): 2233-42.
- Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell*. 1997; 88:131-141.
- Irani BG, Xiang Z, Yarandi HN, Holder JR, Moore MC, Bauzo RM, Proneth B, Shaw AM, Millard WJ, Chambers JB, Benoit SC, Clegg DJ, Haskell-Luevano C. Implication of the

- melanocortin-3 receptor in the regulation of the food intake. *European Journal of Pharmacology*. 2011; 660(1): 80-7.
- Jacobowitz DM, O'Donohue TL. Alpha-melanocyte-stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain. *Proc. Natl. Acad. Sci. USA*. 1978; 75: 6300-04.
- Jansen A, Theunissen N, Slechten K, Nederkooi C, Boon B, Mulkens S, Roefs A. Overweight children overeat after exposure to food cues. *Eating behavior*. 2003; 4: 197-209.
- Jansone D, Bergstrom L, Svirskis S, Lindblom J, Klusa V, Wikberg JES. Opposite effects of  $\delta_1$ - and  $\delta_2$ -melanocyte stimulating hormone on regulation of the dopaminergic mesolimbic system in rats. *Neuroscience Letters*. 2004; 361(1-3): 68-71.
- Jog MS, Kubota Y, Connolly CI, Hillegaart V, Graybiel AM. Building neural representations of habits. *Science*. 1999; 286: 1745-9.
- Joseph SA, Michael GJ. Efferent ACTH-IR opiocortin projections from nucleus tractus solitaries: a hypothalamic deafferentation study. *Peptides*. 1988; 9: 193-201.
- Kaur G, Kulkarni SK. Studies on modulation of feeding behavior by atypical antipsychotics in female mice. *Prog Neuropsychopharmacol Biol Psychiatry*. 2002; 26: 277-85.
- Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. *The Journal of Neuroscience*. 2002; 22(9): 3309-3311.
- Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. *Proceedings of the Royal Society of London Series B, Containing Papers of a Biological Character Royal Society (Great Britain)*. 1953; 140: 578-96.
- Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. *Journal of Comparative Neurology*. 2003; 457(3): 213-35.
- Klusa V, Svirskis S, Opmane B, Muceniece R, Skujins A, Mutulis F, Wikberg JE, Schiöth HB. Evaluation of behavioral effects of neural melanocortin receptor antagonists injected ICV and in VTA in rats. *Neuropeptides*. 1998; 32(6): 573-80.
- Koob GF. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. *Trends Pharmacol. Sci*. 1992; 13: 177-84.
- Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. *J Neurosci*. 2003; 23: 7-11.
- Krashes MJ, Koda S, Ye CP, Rogan SC, Adams AC, Cusher DS, Maratos-Flier E, Roth BL, Lowell BB. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *J Clin Invest*. 2011; 121(4): 1424-8.
- Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nat Genet*. 1998; 19(2): 155-7.
- Krugel U, Schraft T, Kittner H, Kiess W, Illes P. Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. *Eur J Pharmacol*. 2003; 482(1-3): 185-7.
- Labbe O, Dsarnaud F, Eggerickx D, Vassart G, Parmentier M. Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. *Biochem*. 33: 4543-9.
- Lechan RM, Tatro JB. Hypothalamic melanocortin signaling in cachexia. *Endocrinology*. 2001; 142: 3288-91.

- Lee M, Kim A, Conwell IM, Hruby V, Mayorov A, Cai M, Wardlaw SL. Effects of selective modulation of the central melanocortin-3-receptor on food intake and hypothalamic pomc expression. *Peptides*. 2008; 29: 440-7.
- Lenoir M, Serre F, Cantin L, Ahmed SH. Intense sweetness surpasses cocaine reward. *PLoS One*. 2007; 2(8): e698.
- Lindblom J, Opmane B, Mutulis F, Mutule I, Petrovsha R, Klusa V, Bergstrom L, Wikberg JES. The MC4 receptor mediates alpha-MSH induced release of nucleus accumbens dopamine. *Neurochemistry*. 2001; 12(10): 2155-2158.
- Lindvall O, Bjorklund A. The organization of ascending catecholamine neuron systems in the rat as revealed by glyoxylic acid fluorescence method. *Acta Physiol. Scand*. 1974; 412: 1-48.
- Liu H, Kishi T, Roseberry AG, Cai X, Lee CE, Montez JM, Friedman JM, Elmquist JK. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. *J Neurosci*. 2003; 23(18): 7143-54.
- Luilot A, LeMoal M, Simon H. Differential reactivity of dopaminergic neurons in the nucleus accumbens in response to different behavioral situation: In *in vivo* voltammetric study in free moving rats. *Brain Res*. 1986; 397: 395-400.
- Maffei M, Halaas J, Ravussin E, Pratley RE, Zhang Y, Fei H, Kim S, Lollone R, Ranganathan S et al. Leptin levels in human and rodent: measurements of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat Med*. 1995; 1(11): 1155-61.
- Makinen PI, Koponen JK, Karkkainen AM, Malm TM, Pulkkinen KH, Koistinaho J, Turunen MP, Yla-Herttuala S. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. *J Gene Med*. 2006; 8: 433-41.
- Maldonado-Irizarry CS, Swanson CJ, Kelley AE. Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus. *J Neurosci*. 1995; 15: 6779-88.
- Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. *Physiol. Behav*. 2011; 104(1): 76-81.
- Marks DL, Hruby V, Brookhart G, Cone RD. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). *Peptides*. 2006; 27: 259-64.
- Mayer J, Thomas DW. Regulation of food intake and obesity. *Science*. 1967; 156: 328-37.
- McBride WJ, Murphy JM, Ikemoto S. Localization of the brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. *Behav. Brain Res*. 1999; 101: 129-52.
- McGowan MK, Andrews KM, Grossman SP. Chronic intrahypothalamic infusions of insulin or insulin antibodies alter body weight and food intake in the rat. *Physiol. Behav*. 1992; 51: 753-65.
- Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4R) in neuroendocrine and autonomic control circuits in the brain. *Mol Endocrinol*. 1994; 8: 1298-308.
- Naleid AM, Grace MK, Cummings DE, Levine AS. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. *Peptides*. 2005; 26(11): 2274-9.
- Narita M, Nagurno Y, Hasimoto S, Narita M, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. *J Neurosci*. 2006; 26: 398-405.

- Nicola SM. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. *Annu Rev Neurosci.* 2000; 23: 185-215.
- Nijenhuis WA, Oosterom J, Adan RA. AgRP (83-132) acts as an inverse agonist on the human melanocortin-4 receptor. *Mol Endocrinol.* 2001; 15(1): 164-71.
- Nyugen DM, El-Serag HB. The epidemiology of obesity. *Gastroenterology Clinics of North America.* 2010; 39: 1-7.
- O'Donnell P, Grace AA. Synaptic interactions among excitatory afferents to NAc neurons: hippocampal gating of prefrontal cortical input. *J Neurosci.* 1995; 15: 3622-3639.
- Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. *NCHS Data Brief.* 2012; 82: 1-8.
- Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2000. *JAMA.* 2012; 307(5): 483-90.
- Packard MG, White NM. Lesions of the caudate nucleus selectively impair 'reference memory' acquisition in the radial maze. *Behav Neural Biol.* 1990; 53: 39-50.
- Palkovits M, Mezey E, Eskay RL. Pro-opiomelanocortin-derived peptides (ACTH/  $\beta$ -endorphin/ $\alpha$ -MSH) in brainstem baroreceptor areas of the rat. *Brain Res.* 1987; 436: 323-8.
- Palmiter RD. Is dopamine a physiologically relevant mediator of feeding behavior? *Trends Neurosci.* 2007; 30(8): 375-81.
- Panskepp J, Reilly P, Bishop P, Meeker RB, Vilberg TR, Kastin AJ. Effects of  $\alpha$ -MSH on motivation, vigilance, and brain respiration. *Pharmacol Biochem Behav.* 1976; 5: 59-64.
- Pardini AW, et al. Distribution of insulin receptor substrate-2 in brain areas involved in energy homeostasis. *Brain Res.* 2006; 1112: 169-78.
- Park TH, Carr KD. Neuroanatomical patterns of fos-like immunoreactivity induced by a apalatable meal and meal-paired environment in saline- and naltrexone-treated rats. *Brain Res.* 1998; 805(1-2): 169-80.
- Pecina S, Berridge KC. Opioid eating site in nucleus accumbens shell mediates food intake and hedonic 'liking': map based on microinjection Fos plumes. *Brain Res.* 2000; 863: 71-86.
- Rada P, Tucci S, Murzi E, Hernandez L. Extracellular glutamate increases in the lateral hypothalamus and decreases in the nucleus accumbens during feeding. *Brain.* 1997; 768: 338-40.
- Reynolds A, Leake, D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. *Nat Biotechnol.* 2004; 22(3)L326-330.
- Ritz MC, Lamb RJ, Goldberg SR, Kuher MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. *Science.* 1987; 237: 1219-23.
- Roberts DC, Koob GF. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. *Pharmacol. Biochem. Behav.* 1982; 17: 901-4.
- Roseberry AG. Personal communication. 2012.
- Roseberry AG, Bunemann M, Elavunkal J, Hosey MM. Agonist-dependent delivery of M(2) muscarinic acetylcholine receptors to the cell surface after pertussis toxin treatment. *Mol Pharmacol.* 2001; 59(5): 1256-68.
- Roselli-Reh fuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. *Proc Natl Acad Sci USA.* 1993; 90: 8856-60.



- Salamone JD. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. *Behav Brain Res.* 1994; 61: 117-33.
- Schwarz DS, Hutvagner G, Du T, Aronin N, Zamore PD. Assymetry in the assembly of the RNAi emzyme complex. *Cell.* 2003; 115(2): 199-208.
- Seeley RJ, Yagaloff K, Fisher S, Burn P, Thiele T, et al. Melanocortin receptors in leptin effects. *Nature.* 1997; 390: 349.
- Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. *Endocrinology.* 2003; 144: 544-51.
- Shizgal P, Bielajew C, Corbett D, Skelton R, Yeomans J. Behavioral methods for interfering conduction velocity and anatomical linkage: Pathways connecting rewarding brain stimulation sites. *J. comp. physiol. Psychol.* 1980; 94; 227-37.
- Smith DG, Tzavara ET, Shaw J, Luecke S, Wade M, Davis R, Salhoff C, Nomikos GG, Gehlert DR. Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice. *J Neurosci.* 2005; 25(4): 914-22.
- Steele KE, Prokopowicz GP, Schweitzer MA, Magunsuon TH, Lidor AO, Kuwabawa H, Kumar A, Brasic J, Wong DF. Alterations of central dopamine receptors before and after gastric bypass surgery. *Obesity Surgery.* 2010; 20: 369-74.
- Schwartz MW, Seeley RJ, Weighle DS, Burn P, Campfire LA, Baskin DG. Leptin increases hypothalamic proopiomelanocortin (POMC) mRNA expression in the rostral arcuate nucleus. *Diabetes.* 1997; 46: 2119-23.
- Sutton GM, Travaskis JL, Hulber MW, McMillan RP, Markward NJ, Babin MJ, Meyer EA, Butler AA. Diet-genotype interactions in the development of the obese, insulin-resistant phenotype of C57BL/6J mice lacking melanocortin-3 or -4 receptors. *Endocrinology.* 2006; 147(5): 2183-96.
- Szczycka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. *Neuron.* 2001; 30: 819-29.
- Teitelbaum P, Stellar E. Recovery from the failure to eat produced by hypothalamic lesions. *Science.* 1954; 120: 894-5.
- Torre E, Celis ME. Alpha-MSH injected into the substantia nigra or intraventricularly alters behavior and the striatal dopaminergic activity. *Neurochem int.* 1985; 9(1):85-89.
- Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Simbara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kangawa K, Nakazato M. Ghrelin-induced food intake is mediated via the orexin pathway. *Endocrinology.* 2003; 144(4): 1506-12.
- Trigo FF, Boulhours B, Rostaing P, Papageorgiou G, Corrie JE, Triller A, Ogden D, Marty A. Presynaptic miniature GABAergic currents in developing interneurons. *Neuron.* 2010; 66(2): 235-47.
- Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. *Behavioral Pharmacology.* 2002; 13: 355-66.
- Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. *Mol. Psychiatry.* 2004; 9: 557-569.
- Wang GJ, Volkow ND, Fowler JS. The role of dopamine in motivation for food in humans: implications for obesity. *Expert Opin Ther Targets.* 2002; 6: 601-9.

- Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. Brain dopamine and obesity. *Lancet*. 2001; 357: 354-7.
- Weingarten HP. Conditioned cues elicit feeding in sated rats: a role for learning in meal initiation. *Science*. 1983; 220: 431-433.
- Wise RA. Intracranial self-stimulation: mapping against lateral boundaries of the dopaminergic cells of the substantia nigra. *Brain Research*. 1981; 213(1): 190-194.
- Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. *Behav. Brain Sci*. 1982; 5: 39-87.
- Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DGA, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. *Endocrinology*. 2000; 141(11): 4325-8.
- Xenakis S, Sclafani S. The dopaminergic mediation of a sweet reward in normal and VMH hyperphagic rats. *Pharmac Biochem Behav*. 1982; 16(2): 293-302.
- Xenakis S, Sclafani S. The effects of pimozide on the consumption of a palatable saccharin-glucose solution in the rat. *Pharmac. Biochem. Behav*. 1981; 15: 435-42.
- Yaswen L, Diehl N, Breenan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. *Nat Med*. 1999; 5(9):1066-70.
- Yeomans JS. Absolute refractory periods of self-stimulation neurons. *Physiol. Behav*. 1979; 22: 911-919.
- Yoshida M, Yokoo H, Mizoguchi K, Kawahara H, Tsuda A, Nishikawa T, Tanaka M. Eating and drinking cause increased dopamine release in the nucleus accumbens and ventral tegmental area in the rat: measurement in vivo microdialysis. *Neuroscience Letters*. 1992; 139: 73-6.
- Young AMJ, Joseph MH, Gray JA. Increased dopamine release in vivo in nucleus accumbens and caudate nucleus of the rat during drinking: a microdialysis study. *Neuroscience*. 1992; 48: 871-76.
- Zahm DS, Brog JS. On the significance of the subterritories in the "accumbens" part of the rat ventral striatum. *Neuroscience*. 1992; 50: 751-767.
- Zhang M, Kelley AE. Enhanced intake of high-fat food after striatal mu-opioid stimulation: microinjection mapping and fos expression. *Neuroscience*. 2000; 99: 267-277.
- Zhang M, Kelley AE. Opiate agonists microinjected into the nucleus accumbens enhances sucrose drinking in rats. *Psychopharmacology*. 1997; 132(4): 350-60.
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature*. 1994; 372(6505): 425-423.
- Zheng H, Patterson LM, Berthoud HR. Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. *J Neurosci*. 2007; 27: 11075-82.
- Zheng H, Townsend RL, Shin AC, Patterson LM, Phifer CB, Berthoud HR. High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockage and MC3/4R-stimulation. *Brain Res*. 2010; 1350: 131-8.
- Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. *Cell*. 1995; 83(7): 1179-209.